Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD
- 1 January 2017
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 85, 68-78
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expressionWorld Journal of Gastroenterology, 2016
- Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysisJournal of Clinical Biochemistry and Nutrition, 2016
- NAFLD: A multisystem diseaseJournal of Hepatology, 2015
- Gemfibrozil attenuates the inflammatory response and protects rats from abdominal sepsisExperimental and Therapeutic Medicine, 2015
- Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experienceDiabetologia, 2012
- High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα–FoxO3a–PGC-1α pathwayNephrology Dialysis Transplantation, 2011
- An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected IndividualJournal of the International Association of Physicians in AIDS Care, 2011
- Deficient renal 20-HETE release in the diabetic rat is not the result of oxidative stressAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental studyBMC Gastroenterology, 2007
- Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?Nephrology Dialysis Transplantation, 2000